CRYAB, a frequently occurring inhibitor in BLCA, hinders the movement and infiltration of tumor cells by blocking the activation of the PI3K/AKT and ERK signaling pathways, thus impeding tumor cell migration and invasion (Ruan et al., 2020). This evidence concerns the gene AKT1 and bladder transitional cell carcinoma.